The EMJ Podcast | Episode 160
Mark Sullivan, Medicines for Global Health (MDGH), Melbourne, Australia, joins Jonathan to discuss global health inequality, the difficulties in finding funding as a Managing Director of a not-for-profit pharmaceutical company, and infectious diseases such as Hanson’s disease and river blindness.
Mark Sullivan earned a BSc in biochemistry and microbiology from Deakin University, Geelong, Australia, and then started a career in the pharmaceutical world. He has worked for GlaxoSmithKline (GSK), London, UK, and Gilead Sciences, Foster City, California, USA. Sullivan was also the Chief Operating Officer of Australia’s vaccine design and development consortium at the University of New South Wales, Sydney, Australia. Since then, he has contributed to three successful global registrational programmes for HIV and hepatitis B therapeutics, has worked on 40 small molecule and biologic development programmes, and led the development of moxidectin through the U.S. Food and Drug Administration (FDA).
In 2019, Sullivan was the Victorian Australian of the Year, and in 2022 he was awarded Officer of the Order of Australia in the Australia Day Honours List.